Evotec stock sits at EUR 2.80, 63.6 percent below its high

Published on 10/09/2026 at 18:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock was at EUR 2.80 on October 9, 2026, down 1.06 percent. The 52-week high is EUR 7.70 and Berenberg keeps a EUR 3.60 target.

Key points in brief

Evotec stock was at EUR 2.80 at Lang & Schwarz on October 9, 2026, down 1.06 percent versus EUR 2.83.
The price stood 63.60 percent below the EUR 7.70 52-week high recorded on October 8, 2026.
Berenberg kept a Hold rating and a EUR 3.60 target on September 25, 2026.
Evotec is scheduled to publish third-quarter figures on November 5, 2026.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec stock was at EUR 2.80 at Lang & Schwarz on October 9, 2026 at 6:12 p.m. CEST, down 1.06 percent versus the prior close of EUR 2.83. The price stood 63.60 percent below the EUR 7.70 52-week high recorded on October 8, 2026.

Price remains near yearly low

The after-hours quote leaves Evotec close to its EUR 2.73 52-week low listed on October 8, 2026. That places the stock EUR 0.07 above the low and keeps the range as the main technical reference for the session.

The Lang & Schwarz bid was EUR 2.78 and the ask was EUR 2.81 at the same timestamp. The narrow EUR 0.03 spread gives the latest quote a clear trading band for German investors.

Valuation stays loss-making

Evotec's market capitalization was USD 547.1 million on October 9, 2026, while the listed price-to-earnings ratio was minus 2.50. The negative ratio reflects the company's reported loss position and makes the EUR price range more informative than a conventional earnings multiple.

Börse Express reported that Berenberg kept its Hold rating and EUR 3.60 target on September 25, 2026. That target is EUR 0.80 above the Lang & Schwarz price, a difference of 28.57 percent based on the current euro quote.

Comparison with peers

Evotec: minus 1.06 percent, P/E minus 2.50, market capitalization USD 547.1 million
BioNTech (Nasdaq, USD): plus 3.76 percent, P/E minus 12.51, market capitalization USD 24.0 billion
DAX (Germany): plus 0.60 percent, P/E, market capitalization

Next date is November 5

FinanzNachrichten.de identifies November 5, 2026 as the date for Evotec's third-quarter figures. The appointment gives the market a defined checkpoint for testing whether the restructuring can improve the operating picture.

At Lang & Schwarz, Evotec was trading at EUR 2.80 after-hours on October 9, 2026 at 6:12 p.m. CEST, down 1.06 percent versus the prior close of EUR 2.83. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.